Медицинская литература. Новинки

 

 

 

 

 

 

Роль цитокинов в развитии острого панкреатита

Вы можете загрузить полный текст статьи в формате pdf

Ключевые слова:

Литература:
1. Wilson P.G., Manji M., Neoptolemos J.P. Acute pancreatitis as a
model of sepsis // J. Antimicrob. Chemother. 1998. V. 41
((Supp lA). Р. 51–63.
2. Варганов М.В., Ситников В.А., Стяжкина С.Н. Иммуноориентированная терапия в комплексном лечении тяжелого
острого панкреатита // Анн. хирур. гепатол. 2008. T. 13.
№ 3. C. 216.
3. Волков А.Н., Ворончихин В.В., Дербенев А.Г. Оптимизация
комплексного консервативного лечения больных острым
деструктивным панкреатитом в реактивной фазе, озонотерапией и иммунокоррекцией // Анн. хирур. гепатол. 2008.
T. 13. № 3. C. 220.
4. Вихрев С.В., Лазарев И.В. Применение мембранного плазмафереза в лечении острого панкреатита // Анн. хирур. гепатол. 2008. T. 13. № 3. C. 273.
5. Ganguly N.N. Are Alcohol Induced Acute Pancreatitis and
Biliary Acute Pancreatitis Two Different Diseases // Offic. J.
Internat. Hepat. Pancreat. Biliar. Assoc. 2006. V. 8 (Suppl. 2).
Р. 197.
6. Kingsnorth A.N., Galloway S.W., Formela L.J. Randomized, double-blind phase II trial of Lexipafant, a plateletactivating factor
antagonist, in human acute pancreatitis // Brit. J. Surg. 1995. V.
82. Р. 1414–1420/
7. Cartmell M.T., Kingsnorth A.N. Acute pancreatitis // Hosp. Med.
2000. V. 61. P. 382–385.
8. Sakorafas G.H., Tsiotou A.G. Etiology and pathogenesis of acute
pancreatitis: current concepts // J. Clin. Gastroenterol. 2000. V.
30. P. 343–356
9. Rahman S.H., Menon Kr.V. Macrophage Migration Inhibitory
Factor is an Early Marker of Pancreatic Necrosis in Acute
Pancreatitis // Offic. J. Internat. Hepat. Pancreat. Biliar. Assoc.
2006. V. 8 (Suppl. 2). P. 164.
10. Yip V.S.K., Powell J.J., Bellamy C.O. Changes in the Systemic
Innate Immune Response in two Experimental Models of Acute
Pancreatitis // Offic. J. Internat. Hepat. Pancreat. Biliar. Assoc.
2006. V. 8 (Suppl. 2). P. 46.
11. Bone R.C. Sir Isaac Newton, sepsis, SIRS, and CARS // Crit.
Care Med. 1996. V. 24. P. 1125–1128.
12. Davies M.G., Hagen P.O. Systemic inflammatory response syndrome // Brit. J Surg. 1997. V. 84. P. 920–935.
13. Bone R.C. Immunologic dissonance: a continuing evolution in
our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome
(MODS) // Ann. Intern. Med. 1996. V. 125. P. 680–687.
14. Сотченко Б.А., Сапиенко С.В. Возможности прогнозирования течения острого деструктивного панкреатита на основании динамики показателей цитокинового статуса // Анн.
хирур. гепатол. 2008. T. 13. № 3. C. 71.
15. Johnson C.D., Kingsnorth A.N., Imrie C.W. et al. Double blind,
randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of
organ failure in predicted severe acute pancreatitis // Gut. 2001.
V. 48. P. 62–69.
16. van Minnen P.L., Timmerman H.M., de Jager W., Konstantinov
S.R. The Systemic Cytokine Response During Experimental
Acute Pancreatitis: Impact of Entarnal Probiotics // Offic. J.
Internat. Hepat. Pancreat. Biliar. Assoc. 2006. V. 8 (Suppl. 2).
P. 56.
17. Radenkovic D., Bajec D., Ivancevic N. Role of Ddimer in early
prediction of severity in acute pancreatitis // Offic. J. Internat.
Hepat. Pancreat. Biliar. Assoc. 2006. V. 8. Suppl. 2). P. 38.
18. Lane J.S., Todd K.E., Gloor B. et al. Platelet activating factor
antagonism reduces the systemic inflammatory response in a
murine model of acute pancreatitis // J. Surg. Res. 2001. V. 99.
P. 365–370.
19. de Beaux A.C., Fearon K.C. Circulating endotoxin, tumour
necrosis factor-alpha, and their natural antagonists in the pathophysiology of acute pancreatitis // Scand. J. Gastroenterol. 1996.
V. 219. P. 43–46.
20. Engelmann H., Novick D., Wallach D. Two tumor necrosis factorbinding proteins purified from human urine. Evidence for
immunological crossreactivity with cell surface tumor necrosis
factor receptors // J. Biol. Chem. 1990. V. 265. P. 1531–1536.
21. Boldin M.P., Varfolomeev E.E., Pancer Z. et al. A novel protein
that interacts with the death domain of Fas/APO1 contains a
sequence motif related to the death domain // J. Biol. Chem.
1995. V. 270. P. 7795–7798.
22. Sandstrom P., Trulsson L., Gasslander T., Svanvik J. Serum
Amino Acid Pattern in Patients with Acute Pancreatitis // Offic.
J. Internat. Hepat. Pancreat. Biliar. Assoc. 2006. V. 8 (Suppl. 2).
P. 200.
23. O’Reilly D.A., Sargen K.D., Dunlop S. et al. Association of
tumour necrosis factor microsatellite haplotypes with chronic
pancreatitis // Brit. J. Surg. 2000. V. 87. P. 362–373.
24. Norman J.G., Fink G.W., Messina J. et al. Timing of tumor
necrosis factor antagonism is critical in determining outcome in
murine lethal acute pancreatitis // Surg. 1996. V. 120.
P. 515–521.
25. Bhandari M., Thomas A.C., Carati C.J. Antagonism Reduces
Hyperenzymemia Associated with acute pancreatitis a Possum
Model // Offic. J. Internat. Hepat. Pancreat. Biliar. Association.
2006. V. 8 (Suppl. 2). P. 56.
26. Grewal H.P., Mohey E.D., Gaber L. et al. Amelioration of the
physiologic and biochemical changes of acute pancreatitis using
an anti-TNF-alpha polyclonal antibody // Am. J. Surg. 1994.
V. 167. P. 214–218.
27. Greenfeder S.A., Nunes P., Kwee L. et al. Molecular cloning and
characterization of a second subunit of the interleukin 1 receptor
complex // J. Biol. Chem. 1995. V. 270. P. 13757–13765.
28. Fink G.W., Norman J.G. Specific changes in the pancreatic
expression of the interleukin 1 family of genes during expermental acute pancreatitis // Cytokine. 1997. V. 9. P. 1023–1027.
29. Norman J.G., Franz M.G., Fink G.S. et al. Decreased mortality of
severe acute pancreatitis after proximal cytokine blockade //
Ann. Surg. 1995. V. 221. P. 625– 631.
30. Mayer J., Rau B., Gansauge F., Beger H.G. Inflammatory mediators in human acute pancreatitis: clinical and pathophysiological implications // Gut. 2000. V. 47. P. 546–552.
31. Smithies A.M., Sargen K., Demaine A.G., Kingsnorth A.N.
Investigation of the interleukin 1 gene cluster and its association
with acute pancreatitis // Pancr. 2000. V. 20 P. 234–240.
32. Fisher C.J.Jr., Dhainaut J.F., Opal S.M. et al. Recombinant
human interleukin 1 receptor antagonist in the treatment of
patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial / Phase III rhIL-1ra Sepsis
Syndrome Study Group // JAMA. 1994. V. 271. P. 1836–1843.
33. Fiorentino D.F., Zlotnik A., Mosmann T.R. et al. IL-10 inhibits
cytokine production by activated macrophages // J. Immunol.
1991. V. 147. P. 3815–3822.
34. Clarke C.J., Hales A., Hunt A., Foxwell B.M. IL-10- mediated
suppression of TNF-alpha production is independent of its ability to inhibit NF kappa B activity // Eur. J. Immunol. 1998.
V. 28. P. 1719–1726.
35. Seitz M., Loetscher P., Dewald B. et al. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from
blood mononuclear cells and fibroblasts // Eur. J. Immunol.
1995. V. 25. P. 1129–1132.
36. Gloor B., Todd K.E., Lane J.S. et al. Mechanism of increased
lung injury after acute pancreatitis in IL-10 knockout mice //
J. Surg. Res. 1998. V. 80. P. 110–114.
37. van Laethem J.L., Eskinazi R., Louis H. et al. Multisystemic production of interleukin 10 limits the severity of acute pancreatitis
in mice // Gut. 1998. V. 43. P. 408–413.
38. Pezzilli R., Billi P., Miniero R., Barakat B. Serum interleukin-10
in human acute pancreatitis // Dig. Dis. Sci. 1997. V. 42.
P. 1469–1472.
39. Berney T., Gasche Y., Robert J. et al Serum profiles of interleukin-6, interleukin-8, and interleukin-10 in patients with
severe and mild acute pancreatitis // Pancreas. 1999. V. 18.
P. 371–377.
40. Dumot J.A., Conwell D.L., Zuccaro G.Jr. et al A randomized,
double blind study of interleukin 10 for the prevention of ERCPinduced pancreatitis //Am. J. Gastroenterol. 2001. V. 96. .
P. 2098–2102.
41. Deviere J., Le Moine O., van Laethem J.L. et al. Interleukin 10
reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography // Gastroenterol. 2001.
V. 120. P. 498–505.
42. van der Poll T., Marchant A., Keogh C.V. et al. Interleukin-10
impairs host defense in murine pneumococcal pneumonia
//J. Infect. Dis. 1996. V. 174. P. 994–1000.
43. Shimada M., Andoh A., Hata K. et al. IL-6 secretion by human
pancreatic periacinar myofibroblasts in response to inflammatory mediators // J. Immunol. 2002. V. 168. P. 861–868.
44. de Beaux A.C., Goldie A.S., Ross J.A. et al. Serum concentrations
of inflammatory mediators related to organ failure in patients
with acute pancreatitis // Brit. J. Surg. 1996. V. 83. P. 349–353.
45. Kaw M., Singh S. Serum lipase, Creactive protein, and interleukin-6 levels in ERCP-induced pancreatitis // Gastrointest.
Endosc. 2001. V. 54. P. 435–440.
46. Zhou W., Levine B.A., Olson M.S. Plateletactivating factor: a
mediator of pancreatic inflammation during cerulein hyperstimulation // Am. J. Pathol. 1993. V. 142. P. 1504–1512.
47. Formela L.J., Wood L.M., Whittaker M., Kingsnorth A.N.
Amelioration of experimental acute pancreatitis with a potent
platelet-activating factor antagonist // Brit. J. Surg. 1994. V. 81.
P. 1783–1785.
48. McKay C.J., Curran F., Sharples C. et al. Prospective placebocontrolled randomized trial of lexipafant in predicted severe
acute pancreatitis // Brit. J. Surg. 1997. V. 84. P.1239–1243.
49. Murphy P.M. The molecular biology of leukocyte chemoattractant receptors // Ann. Rev Immunol. 1994. V. 12. P. 593–633.
50. Yang B.M., Demaine A.G., Kingsnorth A. Chemokines MCP-1
and RANTES in isolated rat pancreatic acinar cells treated with
CCK and ethanol in vitro // Pancreas. 2000. V. 21. P. 22–31.
51. Simovic M.O., Bonham M.J., Abu'Zidan F.M., Windsor J.A.
Antiinflammatory cytokine response and clinical outcome in
acute pancreatitis // Crit. Care Med. 1999. V. 27. P. 2662–2665.
52. Curley P., Nestor M., Collins K. et al. Decreased interleukin-2
production in murine acute pancreatitis: potential for
immunomodulation // Gastroenterol. 1996. V. 110. P. 583–588.
53. Klein W., Tromm A., Griga T. et al. Interleukin-4 and inter-leukin-4 receptor gene polymorphisms in inflammatory bowel
diseases // Genes Immun. 2001. V. 2. P. 287–289.
54. Shimizu T., Shiratori K., Sawada T. et al. Recombinant human
interleukin-11 decreases severity of acute necrotizing pancreatitis in mice // Pancreas. 2000. V. 21. P. 134–140.
55. Rau B., Baumgart K., Paszkowski A.S. et al. Clinical relevance of
caspase-1 activated cytokines in acute pancreatitis: high correlation of serum interleukin-18 with pancreatic necrosis and systemic complications // Crit. Care Med. 2001. V. 29.
P. 1556–1562.

Cytokine Role in Acute Pancreatitis Development

Keywords: